One of the biggest challenges in converting the promise of stem cell therapies into clinical use is to define the elixir that directs the embryonic stem cell to produce the desired fully differentiated specialised cell type. After much tinkering and a little luck researchers at the Hadassah-Hebrew University Medical Centre in Jerusalem have now re